Silo Pharma (Nasdaq: SILO), a developmental-stage psychedelic biopharmaceutical firm, announced today that it has begun a preclinical toxicity study of its novel time-released, dosage-controlled ketamine formulation, designated as SP-26, for the treatment of fibromyalgia. About Silo Pharma Silo Pharma is a biotechnology startup that
Read More
Numinus Wellness Inc.’s (OTCQX: NUMIF) (TSX: NUMI) research division, Numinus Bioscience, recently announced the development of a tea bag containing psilocybin for use in clinical research. If granted appropriate regulatory approvals, this could eventually be used as a treatment for clients in psychedelic-assisted therapy. Numinus strives to be at the cutting edge of psychedelic-assisted therapies
atai has administered the first dosage of their VLS-01 synthetic DMT drug
Recently, clinical-stage psychedelic biotechnology company Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF)
Psychedelic biotechnology company Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) announced today confirmation of regulatory approval from the U.K. Medicines and Healthcare
Biopharmaceutical company Short Wave Pharma Inc. has announced a signed Clinical Trial Agreement with the Sheba Fund for Health Services and Research. Dr. Eitan
Field Trip Health & Wellness Ltd. announced today that the company has filed the necessary listing application to list its common shares
Silo Pharma, Inc. (OTCQB: SILO), a development-stage psychedelic biopharmaceutical firm, announced that the company’s patented topically applied ketamine formulation has completed a
World-class psychedelic biotech firm Biomind Labs Inc. (NEO: BMND) (OTC: BMNDF) (FSE: 3XI) announced that Former FDA Director Dr. Thomas Laughren has
Clinical‐stage natural psychedelic drug development company Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) today announced the company’s participation in Project Solace, the
Evidence-based mental healthcare company Wellbeing Digital Sciences Inc. (NEO: MEDI) (OTC: KONEF) (FRA: SQ2) announced that its wholly-owned subsidiary KGK Science Inc. has entered into
Biopharmaceutical company Journey Colab who are working to unlock the science of psychedelics and build a new model for addiction treatment recently
The first part in the new MAPS Digital Learning initiative is Psychedelic Fundamentals, which introduces those interested in learning to the fundamental
Zylorion announced today the filing of the Company’s third provisional patent application with the United States Patent and Trademark Office (“USPTO”). The
